Company
(symbol)#

Date
filed

Date
comm.

Shares/
units (M)

Price

Shares
out
(M)@

Lead, other
underwriters

Gross
(US$M)

Post-
offering
market
cap (M)%

INITIAL OFFERINGS TOTAL: $445.25M

Ascendis Pharma A/S (Hellerup, Denmark; ASND)1

1/16/15

1/28/15

6.9ADS

$18

23.8

BofA Merrill Lynch (co-lead); Leerink Partners (co-lead); Wells Fargo Securities

$124

$428.4

Flex Pharma Inc. (Boston; FLKS)2

12/29/14

1/29/15

5.4S

$16

17.8

Jefferies (co-lead); Piper Jaffray (co-lead); JMP Securities; Cantor Fitzgerald & Co.; Roth Capital Partners

$86.4

$284.8

Spark Therapeutics Inc. (Philadelphia; ONCE)3

12/30/14

1/30/15

8.05S

$23

24.54

J.P. Morgan (co-lead); Credit Suisse (co-lead); Cowen and Co.; Sanford C. Bernstein

$185

$564.42

Zosano Pharma Inc. (Fremont, Calif.; ZSAN)4

6/24/14

1/27/15

4.5S

$11

11.8

Ladenburg Thalmann (co-lead); Roth Capital Partners (co-lead)

$49.5

$129.8


Number of IPOs in January: 4

Average value of January IPOs: $111.3M

Number of IPOs in 2015: 4

Total raised in IPOs in 2015: $445.25M

Average value of IPOs in 2015: $111.3M

FOLLOW-ON OFFERINGS TOTAL: $3,817.28M

Adamis Pharmaceuticals Corp. (San Diego; ADMP)5

7/2/14

1/9/15

2S

$5

12.67

Oppenheimer & Co. (co-lead); CRT Capital Group; Maxim Group; Mizuho Securities USA

$10

$63.35

Alcobra Ltd. (Tel Aviv; ADHD)6

8/1/14

1/9/15

7.5S

$4

14.7

Piper Jaffray (lead)

$30

$58.8

Alder Biopharma-ceuticals Inc. (Bothell, Wash.; ALDR)7

1/5/15

1/8/15

6.9S

$30.48

37.7

Credit Suisse; Leerink Partners; Wells Fargo; Sanford C. Bernstein

$203.6

$1,149.1

Alnylam Pharmaceuticals Inc. (Cambridge, Mass.; ALNY)8

12/21/12

1/21/15

4.74S

$95.00

82.59

J.P. Morgan Securities (co-lead); Deutsche Bank Securities (co-lead); Barclays Capital; Piper Jaffray; Cowen and Co.; JMP Securities; Needham & Co.

$450

$7,846.05

Auspex Pharmaceuticals Inc. (La Jolla, Calif.; ASPX)9

1/21/15

1/23/15

3.6S

$56.50

31.08

J.P. Morgan (co-lead); Stifel (co-lead); BMO Markets (co-lead); Baird; William Blair

$203.4

$1,756.02

Avalanche Biotechnologies Inc. (Menlo Park, Calif.; AAVL)10

1/5/15

1/5/15

1.76S

$58.92

24.23

Jefferies (co-lead); Cowen and Co. (co-lead); Piper Jaffray (co-lead); William Blair

$103.7

$1,427.63

Biomarin Pharmaceuticals Inc. (San Rafael, Calif.; BMRN)11

10/7/13

1/22/15

9.7S

$93.25

157.1

BofA Merrill Lynch (lead); J.P. Morgan; Morgan Stanley; Barclays; Deutsche Bank Securities

$904.5

$14,649.58

Cempra Pharmaceuticals Inc. (Chapel Hill, N.C.; CEMP)12

12/29/14

1/8/15

5.3S

$24.50

41.98

Morgan Stanley (co-lead); Cowen and Co. (co-lead); Stifel, Nicolaus & Co. (co-lead); Oppenheimer & Co.; Ladenburg Thalmann

$128.63

$1,028.51

Cerus Corp. (Concord, Calif.; CERS)13

11/12/14

1/7/15

12.72S

$5.50

89.9

Cowen and Co. (co-lead); Baird (co-lead); Wedbush Pacgrow Life Sciences (co-lead); Stephens Inc. (co-lead); BTIG; MLV & Co.

$70

$494.45

Epirus Biopharma-ceuticals Inc. (Boston; EPRS)14

9/17/12

1/30/15

9.6S

$5.00

22.52

Leerink Partners (co-lead); Wedbush Pacgrow Life Sciences (co-lead); BTIG

$48

$112.6

Five Prime Therapeutics Inc. (South San Francisco; FPRX)15

12/8/14

1/7/15

3.83S

$22.00

25.34

Citigroup (co-lead); Leerink Partners (co-lead); Wells Fargo Securities (co-lead); Guggenheim Securities; Oppenheimer & Co.

$84.3

$557.48

Intrexon Corp. (Germantown, Md.; NYSE:XON)16

9/5/14

1/22/15

3.75S

$27.00

104.3

J.P. Morgan; BofA Merrill Lynch; Jefferies (co-lead); Griffin Securities; Mizuho Securities

$101.25

$2,816.1

Keryx Biopharma-ceuticals Inc. (New York; KERX)17

1/20/15

1/20/15

9.2S

$12.00

101.14

J.P. Morgan Securities (co-lead); Cowen and Co. (co-lead); Oppenheimer & Co.; Mizuho Securities; JMP Securities; Roth Capital Partners; Ladenburg Thalmann; Brean Capital; H.C. Wainwright & Co.; Maxim Group; MLV & Co.

$110

$1,213.68

Mirati Therapeutics Inc. (San Diego; MRTX)18

9/24/14

1/29/15

2.6S

$20.00

16.13

Citigroup (co-lead); Jefferies (co-lead); Leerink Partners (co-lead)

$51.8

$322.6

Omeros Corp. (Seattle; OMER)19

1/16/15

1/30/15

3.4S and W for 0.75S

$20.03

37.63

Cowen and Co. (co-lead); Wedbush Pacgrow Life Sciences (co-lead); Needham & Co.; WBB Securities; Maxim Group; MLV & Co.

$84

$753.73

Otonomy Inc. (San Diego; OTIC)20

1/8/15

1/23/15

2.93S

$29.25

23.72

J.P. Morgan Securities (co-lead); Piper Jaffray; Cowen and Co.; Sanford C. Bernstein

$85.7

$693.81

Ovascience Inc. (Cambridge, Mass.; OVAS)21

11/21/14

1/8/15

2.645S

$50

26.93

J.P. Morgan (co-lead); Credit Suisse (co-lead); Leerink Partners

$132.25

$1,346.25

Puma Biotechnology Inc. (Los Angeles; PBYI)22

1/20/15

1/20/15

1.15S

$190.00

31.27

BofA Merrill Lynch (co-lead); J.P. Morgan (co-lead); Citigroup (co-lead); Leerink Partners; Cowen and Co.

$218.5

$5,941.3

Radius Health Inc. (Waltham, Mass.; RDUS)23

1/20/15

1/23/15

4S

$36.75

36.88

Goldman, Sachs & Co. (co-lead); BofA Merrill Lynch (co-lead); Cowen and Co.

$147

$1,355.34

Stemline Therapeutics Inc. (New York; STML)24

2/12/14

1/8/15

3.8S

$15.75

17.1

Aegis Capital (co-lead); Jefferies (co-lead); Cowen and Co. (co-lead); Roth Capital Partners; Ladenburg Thalmann; H.C. Wainwright

$59.85

$269.33

Synageva Biopharma Corp. (Lexington, Mass.; GEVA)25

1/3/13

1/7/15

2.5S

$94.19

36.37

Goldman, Sachs & Co. (co-lead); J.P. Morgan (co-lead); Cowen and Co.; Baird; Nomura; Suntrust Robinson Humphrey

$282.57

$3,425.69

Verastem Inc. (Boston; VSTM)26

1/8/15

1/23/15

8.35S

$6.50

34.24

Jefferies (co-lead); Leerink Partners (co-lead); Guggenheim Securities (co-lead); Oppenheimer & Co. (co-lead)

$54.28

$222.56

Versartis Inc. (Menlo Park, Calif.; VSAR)27

1/22/15

1/22/15

4.35S

$17.25

28.14

Citigroup Global Markets (co-lead); Credit Suisse Securities (co-lead); Cowen and Co. (co-lead); Canaccord Genuity; Suntrust Robinson Humphrey

$75

$485.42

Vitae Pharmaceuticals Inc. (Fort Washington, Pa.; VTAE)28

1/20/15

1/23/15

3.45S

$11.90

21.85

BMO Capital Markets (co-lead); Piper Jaffray (co-lead); Stifel (co-lead); JMP Securities; Wedbush Pacgrow Life Sciences

$41.06

$260.02

Zafgen Inc. (Boston; ZFGN)29

1/20/15

1/23/15

3.94S

$35.00

26.65

Leerink Partners (co-lead); Cowen and Co. (co-lead); Canaccord Genuity; JMP Securities

$137.9

$932.75


Number of follow-on offerings in January: 25

Average value of January follow-ons: $152.69M

Number of follow-on offerings in 2015: 25

Total raised in follow-ons in 2015: $3,817.28M

Average value of follow-ons in 2015: $152.69M

Notes

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics.

1 Ascendis's 6.9M ADS represent 6.9M shares. Includes overallotment option: 900,000 ADS.

2 Flex Pharma's overallotment option: 810,000 shares.

3 Includes Spark's overallotment option: 1.05M shares.

4 Zosana also sold $15M worth of stock in a concurrent private placement with Eli Lilly and Co. Overallotment option: 675,000 shares.

5 Adamis' overallotment option: 300,000 shares.

6 Includes Alcobra's overallotment option: 975,000 shares.

7 Includes Alder's overallotment option: 900,000 shares.

8 Alnylam's overallotment option: 710,526 shares. It is conducting a concurrent private placement with Sanofi SA company Genzyme Corp., which will buy enough shares directly from Alnylam to maintain its 12% ownership.

9 Auspex's shareholders are also selling 1M shares. Overallotment option: 600,000 shares.

10 Avalanche is offering 2M shares, with 237,500 shares coming from existing stockholders. Overallotment option: 147,500 shares from Avalanche, and 152,500 shares from selling stockholders.

11 Includes Biomarin's overallotment option: 1.2M shares.

12 Cempra's overallotment option: 787,500 shares.

13 Cerus's overallotment option: 1.9M shares.

14 Epirus' overallotment option: 1.44M shares.

15 Includes Five Prime's overallotment option: 419,994 shares.

16 Intrexon's overallotment option: 562,500 shares.

17 Keryx's overallotment option: 1.375M shares.

18 Includes Mirati's overallotment option: 337,500 shares.

19 Includes Omeros' overallotment option: 449,325 shares.

20 Includes Otonomy's overallotment option: 382,500 shares.

21 Includes Ovascience's overallotment option: 345,000 shares.

22 Includes Puma's overallotment option: 150,000 shares.

23 Radius' overallotment option: 600,000 shares.

24 Stemline Therapeutics' overallotment option: 570,000 shares of common stock.

25 Synageva's overallotment option: 450,000 shares.

26 Includes Verastem's overallotment option: 1.1M shares.

27 Versartis' overallotment option: 652,173 shares.

28 Includes Vitae's overallotment option: 450,000 shares.

29 Includes Zafgen's overallotment option: 514,200 shares of common stock.